Compounds > batanopride
Page last updated: 2024-11-06

batanopride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Batanopride is a selective agonist of the dopamine D3 receptor. It was originally synthesized and studied as a potential treatment for schizophrenia and other psychiatric disorders. Batanopride has shown promise in preclinical studies for its ability to improve cognitive function and reduce negative symptoms in schizophrenia. Its unique selectivity for the D3 receptor makes it a potential therapeutic agent with fewer side effects compared to traditional antipsychotic drugs. However, clinical trials have yielded mixed results, and batanopride is currently not approved for use in humans.'

batanopride: structure given in first source; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID59692
CHEMBL ID38594
SCHEMBL ID184039
MeSH IDM0167317

Synonyms (25)

Synonym
batanopride
bmy-25801
CHEMBL38594 ,
4-amino-5-chloro-n-(2-diethylamino-ethyl)-2-(1-methyl-2-oxo-propoxy)-benzamide
bdbm50023831
102670-46-2
batanoprida
batanoprida [inn-spanish]
benzamide, 4-amino-5-chloro-n-(2-(diethylamino)ethyl)-2-(1-methyl-2-oxopropoxy)-
unii-1at99k728n
batanopride [inn]
batanopridum [inn-latin]
batanopridum
1at99k728n ,
batanopride [who-dd]
4-amino-5-chloro-n-(2-(diethylamino)ethyl)-2-((1-methylacetonyl)oxy)benzamide
batanopride, (+/-)-
(+/-)-batanopride
SCHEMBL184039
ZYOJXUNLLOBURP-UHFFFAOYSA-N
4-amino-2-(butan-2-on-3-yl)oxy-5-chloro-n-[2-(diethylamino)ethyl]benzamide
4-amino-2-(2-butanon-3-yl)oxy-5-chloro-n-[2-(diethylamino)ethyl]benzamide
Q4868616
4-amino-5-chloro-n-[2-(diethylamino)ethyl]-2-(3-oxobutan-2-yloxy)benzamide
DTXSID20869373

Research Excerpts

Dosage Studied

The evidence suggests that this dosing schedule for batanopride may be too toxic for clinical use.

ExcerptRelevanceReference
" We conducted a randomized, double-blinded, 7 arm clinical trial to: (1) identify the presence of a dose-response for complete protection from emesis, and (2) compare batanopride with a standard antiemetic, methylprednisolone if a dose-response was found not to exist."( A randomized, double-blinded study comparing six doses of batanopride (BMY-25801) with methylprednisolone in patients receiving moderately emetogenic chemotherapy.
Findlay, B; Kaizer, L; Laberge, F; Latreille, J; Lofters, WS; Osoba, D; Pater, J; Rusthoven, J; Warr, D; Wilson, K, 1991)		0.72
" Overall, the evidence suggests that this dosing schedule for batanopride may be too toxic for clinical use."( Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis.
Fleming, GF; Francher, D; Janisch, L; McEvilly, JM; Smaldone, L; Vokes, EE, 1991)		0.76
" Although zacopride potentiated the locomotor decrement to radiation, no clear dose-response relationship was evident."( Effects of zacopride and BMY25801 (batanopride) on radiation-induced emesis and locomotor behavior in the ferret.
King, GL; Landauer, MR, 1990)		0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)1.00000.00010.54948.4000AID64290
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID60668In vivo protection against cisplatin-induced emesis in dog measured as emetic episodes for twice the dose of 0.3 mg/kg and in 5 ferrets1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID60604In vivo antagonism of cisplatin-induced emesis in dog measured as percentage protection for twice the dose of 0.3 mg/kg in 2 dogs1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID72406In vivo protection against cisplatin-induced emesis in ferret measured as percentage protection for twice the dose of 2.7 mg/kg and in 0.1 ferrets1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID60601In vivo antagonism of cisplatin-induced emesis in dog measured as percentage protection for twice the dose of 0.1 mg/kg in 2 dogs1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID60613In vivo protection against cisplatin-induced emesis in dog measured as percentage protection for twice the dose of 0.1 mg/kg and in 3 ferrets1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID176969In vivo antagonism activity against D2 receptor was measured as stereotypy in rat when administered subcutaneously1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID72404In vivo protection against cisplatin-induced emesis in ferret measured as percentage protection for twice the dose of 0.3 mg/kg and in 6 ferrets1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID72405In vivo protection against cisplatin-induced emesis in ferret measured as percentage protection for twice the dose of 0.9 mg/kg and in 6 ferrets1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID60515In vivo antagonism of cisplatin-induced emesis in dog measured as emetic episodes, twice the dose of 0.1 mg/kg in 2 dogs1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID60667In vivo protection against cisplatin-induced emesis in dog measured as emetic episodes for twice the dose of 0.1 mg/kg and in 3 ferrets1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID176973In vivo antagonistic activity against dopamine D2 receptor was measured as catalepsy in rat when administered subcutaneously1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID60614In vivo protection against cisplatin-induced emesis in dog measured as percentage protection twice the dose of 0.1 mg/kg and in 3 ferrets1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID72083In vivo protection against cisplatin-induced emesis in ferret measured as emetic episodes for twice the dose of 2.7 mg/kg and in 3 ferrets1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID72081In vivo protection against cisplatin-induced emesis in ferret measured as emetic episodes for twice the dose of 0.1 mg/kg and in 3 ferrets1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID72399In vivo antagonism of cisplatin-induced emesis in ferret measured as percentage protection for twice the dose of 3 mg/kg and in 0.3 ferrets1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID59839In vitro cisplatin-induced emesis in dog was measured for as stereotypy in dog when administered iv twice daily1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID72061Cisplatin-induced emesis in ferret measured as stereotypy in dog when administered iv (in vitro) twice daily1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID72082In vivo protection against cisplatin-induced emesis in ferret measured as emetic episodes for twice the dose of 0.3 mg/kg and in 6 ferrets1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID72398In vivo antagonism of cisplatin-induced emesis in ferret measured as percentage protection for twice the dose of 3 mg/kg and in 0.1 ferrets1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID60669In vivo protection against cisplatin-induced emesis in dog measured as emetic episodes for twice the dose of 0.9 mg/kg and in 3 ferrets1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID72070In vivo antagonism of cisplatin-induced emesis in ferret measured as emetic episodes, twice the dose of 0.1 mg/kg and in 3 ferrets1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID72084In vivo protection against cisplatin-induced emesis in ferret measured as p emetic episodes for twice the dose of 0.9 mg/kg and in 6 ferrets1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID72072In vivo antagonism of cisplatin-induced emesis in ferret measured as emetic episodes, twice the dose of 0.3 mg/kg and in 3 ferrets1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID72403In vivo protection against cisplatin-induced emesis in ferret measured as percentage protection for twice the dose of 0.1 mg/kg and in 3 ferrets1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID60519In vivo antagonism of cisplatin-induced emesis in dog measured as emetic episodes, twice the dose of 0.3 mg/kg in 2 dogs1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID72078In vivo antagonism of cisplatin-induced emesis in ferret measured as emetic episodes, twice the dose of 3 mg/kg and in 3 ferrets1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID60523In vivo antagonism of cisplatin-induced emesis in dog measured as emetic episodes, twice the dose of 1 mg/kg in 2 dogs1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID60607In vivo antagonism of cisplatin-induced emesis in dog measured as percentage protection for twice the dose of 1 mg/kg in 2 dogs1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID64290In vitro antagonistic activity against Dopamine receptor D2 was evaluated for the inhibition of [3H]spiperone binding1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID59841In vivo antagonism activity against dopamine D2 receptor was measured as emesis in dog when administered subcutaneously1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (16.67)18.7374
1990's10 (83.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.16 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.99 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (33.33%)5.53%
Reviews2 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (50.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
2-methyl-5-ht
2-methyl-5-HT: M-receptor agonist		1.9710tryptaminesserotonergic agonist
domperidone
Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.. domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.		1.9710benzimidazoles;
heteroarylpiperidine		antiemetic;
dopaminergic antagonist
metoclopramide
Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.. metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.		13.02124benzamides;
monochlorobenzenes;
substituted aniline;
tertiary amino compound		antiemetic;
dopaminergic antagonist;
environmental contaminant;
gastrointestinal drug;
xenobiotic
ondansetron
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.		1.9710carbazoles
apomorphine
Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.		1.9710aporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug
methylprednisolone
Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.		10.43226-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic
indazoles
Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.		2.3820indazole
zacopride
[no description available]		7.6730benzamides
tropisetron
Tropisetron: An indole derivative and 5-HT3 RECEPTOR antagonist that is used for the prevention of nausea and vomiting.. tropisetron : An indolyl carboxylate ester obtained by formal condensation of the carboxy group of indole-3-carboxylic acid with the hydroxy group of tropine.		1.9710indolyl carboxylic acid
bemesetron
[no description available]		1.9710
dolasetron
[no description available]		1.9710indolyl carboxylic acid
granisetron
Granisetron: A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic for cancer chemotherapy patients.. granisetron : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 1-methyl-1H-indazole-3-carboxylic acid with the primary amino group of (3-endo)-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine. A selective 5-HT3 receptor antagonist, it is used (generally as the monohydrochloride salt) to manage nausea and vomiting caused by cancer chemotherapy and radiotherapy, and to prevent and treat postoperative nausea and vomiting.		5.1531aromatic amide;
indazoles
ConditionIndicatedRelationship StrengthStudiesTrials
Anochlesia
[description not available]		01.9710
Nausea
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.		04.6821
Benign Neoplasms
[description not available]		05.1521
Emesis
[description not available]		07.1783
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		05.1521
Vomiting
The forcible expulsion of the contents of the STOMACH through the MOUTH.		07.1783
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		01.9810
Blood Pressure, Low
[description not available]		04.3322
Diarrhea
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.		03.3611
Hypotension
Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.		09.3322
Experimental Radiation Injuries
[description not available]		01.9710